Sponsor Deadline
Posted: 3/18/2024

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.  This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA   

This FOA runs in parallel with another FOA of identical scientific scope, PAR-22-090, which accepts applications that do or do not propose clinical trial(s).


  • R21 Deadlines: Feb. 16, Jun. 16, Oct. 16

PAR-22-091 Expiration Date: January 8, 2025

Amount Description

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.